Mantle Cell Lymphoma (MCL) Recruiting Phase 2 Trials for Obinutuzumab (DB08935)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03311126Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell LymphomaTreatment
NCT03229382Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem CellTreatment